High throughput sequencing technologies have facilitated an outburst in biological knowledge over the past decades and thus enables improvements in personalized medicine. In order to support (international) medical research with the combination of genomic and clinical patient data, a standardization and harmonization of these data sources is highly desirable. To support this increasing importance of genomic data, we have created semantic mapping from raw genomic data to both FHIR (Fast Healthcare Interoperability Resources) and OMOP (Observational Medical Outcomes Partnership) CDM (Common Data Model) and analyzed the data coverage of both models. For this, we calculated the mapping score for different data categories and the relative data coverage in both FHIR and OMOP CDM. Our results show, that the patients genomic data can be mapped to OMOP CDM directly from VCF (Variant Call Format) file with a coverage of slightly over 50%. However, using FHIR as intermediate representation does not lead to further information loss as the already stored data in FHIR can be further transformed into OMOP CDM format with almost 100% success. Our findings are in favor of extending OMOP CDM with patient genomic data using ETL to enable the researchers to apply different analysis methods including machine learning algorithms on genomic data.

Current challenges of rare diseases need to involve patients, physicians, and the research community to generate new insights on comprehensive patient cohorts. Interestingly, the integration of patient context has been insufficiently considered, but might tremendously improve the accuracy of predictive models for individual patients. Here, we conceptualized an extension of the European Platform for Rare Disease Registration data model with contextual factors. This extended model can serve as an enhanced baseline and is well-suited for analyses using artificial intelligence models for improved predictions. The study is an initial result that will develop context-sensitive common data models for genetic rare diseases.

Background: The emergence of collaborations, which standardize and combine multiple clinical databases across different regions, provides a wealthy source of data, which is fundamental for clinical prediction models, such as patient-level predictions. With the aid of such large data pools, researchers are able to develop clinical prediction models for improved disease classification, risk assessment, and beyond. To fully utilize this potential, Machine Learning (ML) methods are commonly required to process these large amounts of data on disease-specific patient cohorts. As a consequence, the Observational Health Data Sciences and Informatics (OHDSI) collaborative develops a framework to facilitate the application of ML models for these standardized patient datasets by using the Observational Medical Outcomes Partnership (OMOP) common data model (CDM). Motivation: In this study, we compare the feasibility of current web-based OHDSI approaches, namely ATLAS and “Patient-level Prediction” (PLP), against a native solution (R based) to conduct such ML-based patient-level prediction analyses in OMOP. This will enable potential users to select the most suitable approach for their investigation. Methods: Each of the applied ML solutions was individually utilized to solve the same patient-level prediction task. Both approaches went through an exemplary benchmarking analysis to assess the weaknesses and strengths of the PLP R-Package. In this work, the performance of this package was subsequently compared versus the commonly used native R-package called Machine Learning in R 3 (mlr3), and its sub-packages. The approaches were evaluated on performance, execution time, availability of tools for handling imbalanced datasets, and ease of model implementation. Results: The results show that the PLP package has shorter execution times, which indicates great scalability, as well as intuitive code implementation, and numerous possibilities for visualization. However, limitations in comparison to native packages were depicted in the implementation of specific ML classifiers (e.g., Lasso), which may result in a decreased performance for real-world prediction problems. Conclusion: The findings here contribute to the overall effort of developing ML-based prediction models on a clinical scale and provide a snapshot for future studies that explicitly aim to develop patient-level prediction models in OMOP CDM.